logo-loader
RNS
4basebio PLC

4basebio Plc - Grant of Options & Director/PDMR Dealing

A blue text on a black backgroundAI-generated content may be incorrect.

4basebio PLC

("4basebio" or the "Company")

 

 

Grant of Options

Director/PDMR Dealing

 

Cambridge, UK – 22 July 2026   –   4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has granted in aggregate 684,872 options over ordinary shares of the Company, (the “ Share Options ") to certain Directors and a PDMR of the Company.

 

634,872 of the Share Options granted to Dr. Amy Walker, Dr. Manja Boerman and Dr. Heikki Lanckriet have an exercise price of £5.05 per ordinary share (breakdown below), being the closing mid-market price on 1 May 2026, and the remaining 50,000 Share Options granted to Richard Bungay have an exercise price of £5.25 per ordinary share, being the closing mid-market price on 21 July 2026.

 

Further details are set out in the Notification of Dealing Form below.

 


                      Number of Share  Resultant Number of  As a % of Current
                     Options Granted  Share Options Held   Issued Share Capital

Dr. Amy Walker       387,872          430,000              2.77%

Dr. Manja Boerman    172,000          172,000              1.11%

Dr. Heikki Lanckriet 75,000           101,137              0.65%

Richard Bungay       50,000           50,000               0.32%

 Total                684,872          753,127              4.85%



 

 

Certain amounts of the Share Options have been granted to Dr. Amy Walker and Dr. Manja Boerman pursuant to delayed option grants that were agreed in 2024 and 2025.

 

301,872 of the Share Options granted to Dr. Amy Walker and all of the Share Options granted to Dr. Manja Boerman vest annually in equal tranches over four years from 1 May 2026. 86,000 of the Share Options granted to Dr. Amy Walker will become exercisable if the volume-weighted average share price of the Company exceeds £15.00 for 30 consecutive trading days. The Share Options granted to Richard Bungay vest annually in equal tranches over four years from 21 July 2026. The Share Options granted to Dr. Heikki Lanckriet vest in full immediately on grant.

 

The issued share capital of the Company is 15,538,518 ordinary shares. Following the grant of the Share Options, the Company will have 1,354,024 options over ordinary shares in issue representing approximately 8.71 per cent. of the Company’s current issued share capital

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

 

For further enquiries, please contact:


 4basebio PLC

Dr. Amy Walker, CEO

+44 (0)12 2396 7943



 Cairn Financial Advisers LLP (Nominated Adviser)

Jo Turner / Sandy Jamieson / Ed Downes

+44 (0)20 7213 0880



 Cavendish Capital Markets Limited (Joint Broker)

Geoff Nash / Nigel Birks

+44 (0)20 7220 0500



 RBC Capital Markets (Joint Broker)

Kathryn Deegan / Matthew Coakes

+44 (0)20 7653 4000



 ICR Healthcare (Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson

+44 (0)203 707 5700



 

 

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.

 

For more information, visit 4basebio.com .

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 _________________________________________________________________________
|  | Details of the persons discharging managerial responsibilities /     |
| 1|person closely associated                                             |
|  |                                                                      |
|  |                                                                      |
|__|______________________________________________________________________|
|  |                               |1)   Dr. Amy Walker                   |
|  |                               |                                      |
|  |                               |2)   Dr. Manja Boerman                |
|  |Name                           |                                      |
|a)|                               |3)   Dr. Heikki Lanckriet             |
|  |                               |                                      |
|  |                               |4)   Richard Bungay                   |
|  |                               |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  | Reason for the notification                                          |
| 2|                                                                      |
|  |                                                                      |
|__|______________________________________________________________________|
|  |                               |1)   Chief Executive Officer          |
|  |                               |                                      |
|  |                               |2)   Executive Chair                  |
|  |                               |                                      |
|  |Position/Status                |3)   Non-executive Director           |
|a)|                               |                                      |
|  |                               |4)   PDMR                             |
|  |                               |                                      |
|  |                               |                                      |
|  |                               |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |Initial notification/ Amendment|Initial notification                  |
|b)|                               |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  | Details of the issuer, emission allowance market participant, auction|
| 3|platform, auctioneer or auction monitor                               |
|  |                                                                      |
|  |                                                                      |
|__|______________________________________________________________________|
|  |Name                           |                                      |
|a)|                               |4basebio plc                          |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |LEI                            |                                      |
|b)|                               |213800E2DX9EAIUNCB30                  |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  | Details of the transaction(s): section to be repeated for (i) each   |
|  |type of instrument; (ii) each type of transaction; (iii) each date;   |
| 4|and (iv) each place where transactions have been conducted            |
|  |                                                                      |
|  |                                                                      |
|__|______________________________________________________________________|
|  |Description of the financial   |                                      |
|  |                               |                                      |
|  |instrument, type of            |                                      |
|  |                               |                                      |
|  |instrument                     |                                      |
|  |                               |Options over Ordinary Shares          |
|a)|                               |                                      |
|  |                               |                                      |
|  |Identification code            |                                      |
|  |                               |                                      |
|  |                               |ISIN: GB00BMCLYF79                    |
|  |                               |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |                               |Grant of Options over Ordinary Shares |
|b)|Nature of the transaction      |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |                               | ____________________________________ |
|  |                               ||Price(s) per share (p)|Volume(s)    ||
|  |                               ||______________________|_____________||
|  |                               ||i)   505p             |             ||
|  |                               ||                      |i)   387,872 ||
|  |Price(s) and volume(s)         ||ii)   505p            |             ||
|c)|                               ||                      |ii)   172,000||
|  |                               ||iii)   505p           |             ||
|  |                               ||                      |iii)   75,000||
|  |                               ||iv)   525p            |             ||
|  |                               ||                      |iv)   50,000 ||
|  |                               ||                      |             ||
|  |                               ||______________________|_____________||
|__|_______________________________|______________________________________|
|  |Aggregated information         |                                      |
|  |                               |                                      |
|  |                               |                                      |
|  |                               |                                      |
|  |-             Aggregated volume|                                      |
|d)|                               |                                      |
|  |                               |See above                             |
|  |                               |                                      |
|  |-             Aggregated Price |                                      |
|  |                               |                                      |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |Date of transaction            |                                      |
|e)|                               |21 July 2026                          |
|  |                               |                                      |
|__|_______________________________|______________________________________|
|  |Place of transaction           |                                      |
|f)|                               |Outside a trading venue               |
|  |                               |                                      |
|__|_______________________________|______________________________________|


 

 





4376666_0.png




NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

35 min read